Bicara Therapeutics Inc.
BCAX evidence brief
What we can confirm
- BioSniper Score:
- 5.4 / 10
- Market Cap:
- $1.54B
- Lead Asset:
- ficerafusp alfa (formerly BCA101) (Phase 3)
What it means
What to watch
Prepared research question
What matters most for BCAX—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · BCAX
Bicara Therapeutics Inc. (BCAX) is a clinical-stage biopharmaceutical company developing ficerafusp alfa, a bifunctional antibody targeting EGFR and TGF-β, for head and neck squamous cell carcinoma, with a pivotal Phase 2/3 trial underway and an interim readout expected in mid-2027.
Key risk: No approved product revenue
BioSniper Score
Based on 4 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 1 pipeline candidate for Bicara Therapeutics Inc..
Bicara Therapeutics Inc. (BCAX) is a clinical-stage biopharmaceutical company developing ficerafusp alfa, a bifunctional antibody targeting EGFR and TGF-β, for head and neck squamous cell carcinoma, with a pivotal Phase 2/3 trial underway and an interim readout expected in mid-2027.
- Cash & equivalents of $96.6M as of 2026-06-30 [sec].
- Net loss of $55.4M for the six months ended 2026-06-30 [sec].
- Shareholders' equity of $468.8M as of 2026-06-30 [sec].
- Pivotal FORTIFI-HN01 Phase 2/3 trial in HPV-negative head and neck cancer is enrolling; interim analysis expected mid-2027 [news · published 2026-08-11].
- Granted FDA Breakthrough Therapy Designation for ficerafusp alfa in combination with pembrolizumab in 1L HPV-negative R/M HNSCC [news · published 2025-11-10].
What works
- Cash runway into the first half of 2029 provides extended non-dilutive funding for clinical development [news · published 2026-08-11].
- FDA Breakthrough Therapy Designation for the lead program may accelerate regulatory review [news · published 2025-11-10].
- Leadership transition with a new CEO effective January 2027 signals planned execution focus [news · published 2026-08-11].
What to weigh
- Net loss of $55.4M in the first half of 2026 reflects ongoing high R&D spending with no approved product revenue [sec].
- The pivotal trial's interim readout is not expected until mid-2027, leaving a long period without a major catalyst [news · published 2026-08-11].
- Competitive landscape includes pembrolizumab-based regimens and BioNTech's BNT113, posing market risk [pipeline].
From the filings
Quoted directly from source documents.
Cash runway into first half of 2029
“reaffirming its cash runway into the first half of 2029”
News · August 11, 2026
Interim analysis expected mid-2027
“topline results from interim analysis in mid-2027”
News · August 11, 2026
FDA Breakthrough Therapy Designation
“Granted FDA Breakthrough Therapy Designation for ficerafusp alfa in combination with pembrolizumab in 1L HPV-negative R/M HNSCC”
News · November 10, 2025
Net loss of $55.44 million in Q2 2026
“wider net loss of US$55.44 million”
News · August 13, 2026
Catalyst timeline
- 2025-01-28 · Phase 3 Start of FORTIFI-HN01 — Initiation of the pivotal Phase 2/3 trial for ficerafusp alfa in head and neck cancer.
- 2026-08-11 · Earnings Call Q2 2026 — Company reported Q2 2026 financial results and business updates.
- 2026-09-01 · Phase 2 Start of FORTIFI-FLEX — Initiation of a Phase 2 study evaluating an alternative dosing regimen of ficerafusp alfa.
Risks & what to watch (3)›
Key risks
- No approved product revenue — Company has no marketed products; all revenue is zero, relying solely on cash reserves and equity [sec].
- Competitive pressure — Faces competition from pembrolizumab-based regimens and BioNTech's BNT113 in head and neck cancer [pipeline].
- Long wait for catalyst — Next major clinical catalyst (interim readout) not expected until mid-2027 [news · published 2026-08-11].
What to watch
- Enrollment progress and interim analysis of FORTIFI-HN01 trial, expected mid-2027 [news · published 2026-08-11].
- Leadership transition: Ryan Cohlhepp becomes CEO in January 2027 [news · published 2026-08-11].
- Cash burn rate and whether cash runway extends into H1 2029 as stated [news · published 2026-08-11].
- Any updates on the FORTIFI-FLEX alternate dosing study initiated in 2026 [news · published 2026-08-11].
Sources: Catalysts · News · Pipeline · Generated October 11, 2026 · How we verify sources →
Run Bicara Therapeutics Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Bicara Therapeutics Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
Cash runway data unavailable
D/E 0.09 · 0% dilution
Lead: Phase 3
1 candidate
No upcoming catalysts tracked
0 buys · 20 sells (180d)
Pipeline
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
147
Total value held
$1.23B
| Holder | Shares | Value |
|---|---|---|
| ra capital management, l.p. | 7,255,993 | $144.3M |
| siren, l.l.c. | 5,802,970 | $115.4M |
| vestal point capital, lp | 5,425,000 | $107.9M |
| deep track capital, lp | 4,062,500 | $80.8M |
| janus henderson group plc | 3,339,218 | $66.4M |
| red tree management, llc | 3,170,509 | $63.1M |
| tpg gp a, llc | 3,010,425 | $59.9M |
| blackrock, inc. | 2,843,707 | $56.6M |
| omega fund management, llc | 2,392,150 | $47.6M |
| royalty pharma sub-manager, llc | 2,388,150 | $46.7M |
Showing top 10 of 147 institutional holders of Bicara Therapeutics Inc.. Open the full 13F history after sign-in.
Short Interest
as of May 20, 2026- % of float
- 19.0%
- Days to cover
- 15.7
- Shares short
- 8,896,472
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
BCAX short interestGovernance
Frequently asked questions
What is the AI investment thesis for Bicara Therapeutics Inc.?
Bicara Therapeutics Inc. (BCAX) is a clinical-stage biopharmaceutical company developing ficerafusp alfa, a bifunctional antibody targeting EGFR and TGF-β, for head and neck squamous cell carcinoma, with a pivotal Phase 2/3 trial underway and an interim readout expected in mid-2027.
What is Bicara Therapeutics Inc.'s lead drug candidate?
Bicara Therapeutics Inc.'s most advanced tracked candidate is ficerafusp alfa (formerly BCA101) (Phase 3) for Head and Neck Squamous Cell Carcinoma.
Who is the CEO of Bicara Therapeutics Inc.?
Dr. Claire Mazumdar Clemon M.B.A., Ph.D. is the chief executive officer of Bicara Therapeutics Inc. (BCAX).
Where is Bicara Therapeutics Inc. headquartered?
Bicara Therapeutics Inc. (BCAX) is headquartered in Boston, MA, United States.
What therapeutic areas does Bicara Therapeutics Inc. focus on?
Bicara Therapeutics Inc. develops therapies across Oncology, Dermatology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.